Friday, September 18, 2020 11:00 AM EST
Bloomberg Intelligence and inThought host a call with Spinal Muscular Atrophy experts for an in-depth review of the spinal muscular atrophy (SMA) treatment landscape, which now includes approved drugs from Biogen, Novartis and Roche.
- Adrian Krainer, PhD of Cold Spring Harbor Laboratory
- Thomas O. Crawford, M.D. is Director of the MDA clinic for Neuromuscular Disorders at Johns Hopkins
- Marc Engelsgjerd, MD Senior Analyst, Bloomberg Intelligence
- Sam Fazeli, PhD Head of EMEA Research, Bloomberg Intelligence
- Michelle Rivera, PhD Senior Analyst, inThought Research